INO-4800 will more benefit than other Corona vaccines currently in place

Biotech company Kanca Eurogentec, located near the city of Liege, Belgium, is preparing to produce the corona virus vaccine for American company Innovio. In its state-of-the-art fermenter, Eurogentec will manufacture the Covid-19 vaccine ‘INO-4800’. This vaccine will be nucleic-acid based. However, it is unlikely to hit the market before the next six months. “INO-4800” will more benefit than other Corona vaccines currently in place, said Leeuka Janssen, CEO of Kanaka Eurogentec.

Janssen stated, ‘This vaccine can remain stable at room temperature for more than a year and is a tremendous benefit. If you want to start vaccination in developing countries or countries of Africa, Asia, then this vaccine will help you.

He said, this vaccine can remain stable at room temperature compared to other vaccines and for this you will not need refrigerators. Significantly, in less developed countries, keeping the vaccine at a lower temperature is becoming challenging.

Let us tell you that Innovio is a biotechnology company working on bringing DNA-containing drugs to the market to treat and protect people from infectious diseases and cancer. At the same time, the company is now working with Eurojentec to produce the corona vaccine ‘INO-4800’.

INO-4800 will more benefit than other Corona vaccines currently in place
INO-4800 will more benefit than other Corona vaccines currently in place

Innovio has received approval from the Food and Drug Administration (FDA) of the US for Phase II testing of the vaccine. This test is being financially supported by the US Ministry of Defense. Innovio is working to manufacture the vaccine with the goal of producing millions of ‘INO-4800’ vaccine doses for worldwide distribution.

Significantly, the UK has started a vaccination campaign in its country with the vaccine formulated by Pfizer / Bioentech. However, there is a problem with the maintenance of this vaccine, as it requires a temperature of -70 degrees for storage.

There is not much challenge in the use of this vaccine in developed countries and European countries, but storage of this vaccine is becoming challenging in less developed countries of the world. In such a situation, if the ‘INO-4800’ vaccine is ready, it will help the low-income countries against Corona.

%d bloggers like this: